- Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors
- Less Can Be More by Circulating Tumor DNA Use in ERBB2 -Positive Breast Cancer
- Durable Gains and Persistent Questions From the ASTRUM-005 Trial
- Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer
- Prostate Imaging Standards for Screening Magnetic Resonance Imaging (PRISM)
- Fluids for Immune Checkpoint Inhibitor Diabetic Ketoacidosis
- Hypernatremia and Polyuria in a Patient With Metastatic Breast Cancer
- Second Primary Malignant Neoplasms After T-Cell–Engaging Bispecific Antibody Therapy
- Avelumab Plus Methotrexate for Gestational Trophoblastic Tumors
- First-Line Serplulimab in Extensive-Stage Small Cell Lung Cancer
- Fovinaciclib for First-Line Therapy of Advanced Breast Cancer
- One Ovary
- Neoadjuvant Paclitaxel, Trastuzumab, and Pertuzumab for Stage II to III, ERBB2 -Positive Breast Cancer
- Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations
- Fluids for Immune Checkpoint Inhibitor Diabetic Ketoacidosis—Reply
